Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908310 · ClinicalTrials.gov registry record · Phase 4
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
A Phase 4 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 213
- Enrollment target
NCT00908310 is a Phase 4 study that has completed, run by GE Healthcare. The registered enrollment target is 213 participants.
The verdict
NCT00908310, a Phase 4 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 213 participants
- Enrollment target
Study Summary
This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI. Omniscan will be administered intravenously at the medical discretion of the prescribing physician.
Interventions
- DRUG Omniscan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00908310
The ClinicalTrials.gov registry entry for NCT00908310 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omniscan is the first listed.
NCT00908310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00908310 about?
NCT00908310 is a clinical study titled "Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)". This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI. Omniscan will be administered intravenously at the medical discretion of the prescribing physician.
What is the current status of trial NCT00908310?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 213 participants. The study started on 2009-05. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00908310?
The interventions under investigation include: Omniscan (DRUG).
Who is sponsoring clinical trial NCT00908310?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.